1. Introduction {#Section1}
===============

Characterized by abnormal cell metabolism and growth with risk of metastasis, cancer remains a global fatal threat to human health today [@B1], [@B2]. In recent years, cancer starvation therapy is emerging as an effective method for suppressing tumor growth and survival through blocking blood flow or depriving their essential nutrients/oxygen supply [@B3]-[@B5]. The transport of nutrients could be blocked by stopping the tumor blood supply with the treatments of angiogenesis inhibiting agents (AIAs) [@B6], [@B7], vascular disrupting agents (VDAs) [@B8], [@B9] and transarterial chemoembolization (TACE) [@B10]. Moreover, agents that could consume the intratumoral nutrients/oxygen or mediate the essential substances uptake by tumor cells can also lead to tumor "starvation" and necrosis [@B4], [@B5], [@B11], [@B12]. Although some unique advantages have been exhibited for cancer treatment these years, concerns associated with these agents, such as low targeting efficiency, elevated tumor hypoxia, acute coronary syndromes, abnormal ventricular conduction, induced drug resistance and increased tumor metastasis risk, limit their further applications in clinic [@B13]-[@B16].

To overcome these challenges, combination therapy of cancer starvation agents with other cancer treating approaches has demonstrated to be an efficient way, which can maximize the therapeutic efficiency when compared to the single therapeutic method alone [@B17]. However, issues of the free drugs, such as undesirable drug absorption, poor bioavailability and rapid metabolism*in vivo*, have still been concerned [@B18]. The advances in micro-/nanotechnology as well as cancer biology have boosted development of drug delivery systems for cancer management with enhanced efficacy and limited side effects [@B19]-[@B22]. Among them, a variety of nanomaterials based on natural/synthetic polymers [@B23]-[@B29], liposomes [@B30], metal-organic frameworks (MOFs) [@B13], gold nanoparticles (NPs) [@B31] and silica NPs [@B11], [@B32], [@B33] have been employed to co-deliver cancer-starving agents and other therapeutics with the aim of reducing drug side effects [@B23], improving their targeting efficacy [@B26], [@B27], increasing the stability and half-life of therapeutics [@B13], and co-delivery of multiple drugs to overcome the drug resistance [@B34], [@B35]. Furthermore, cancer-starvation strategy associated with the multimodal nanomedicines have also been developed for achieving synergistic cancer therapy, which has been demonstrated to be the efficient way for overcoming the side effects of free drugs and resulting in superadditive therapeutic effects [@B14], [@B15], [@B20].

There are two major mechanisms in designing starving-nanotherapeutics. One is stopping/reducing the tumor blood supply through inhibiting/disrupting angiogenesis, or directly blocking the blood vessels [@B11], [@B23], [@B26], [@B36], [@B37]. The other is depriving essential nutrients/oxygen input of tumor cells through consuming the intratumoral nutrients/oxygen, or limiting the critical nutrients uptake [@B4], [@B38]-[@B40]. For maximizing the therapeutic efficiency, these therapeutics were cooperated with other cancer treating approaches, including chemotherapy [@B41], [@B42], gene therapy [@B43], phototherapy [@B44], [@B45], gas therapy [@B46], and immunotherapy [@B47]. Herein, we overview the recent efforts of leveraging nanomedicine-based drug delivery systems for cancer starvation therapy and focus on the major strategies of multimodal synergistic starvation treatments (**Figure [1](#F1){ref-type="fig"}**). Both the design principles and their anticancer performance of these formulations are highlighted. Finally, the challenges and future prospects of this field are discussed.

2. Nanomedicine-mediated cancer starvation therapy {#Section2}
==================================================

2.1 Antiangiogenesis-related cancer starvation therapy {#Section2.1}
------------------------------------------------------

Tumor growth and metastasis highly depend on the angiogenesis, which is an essential step of neoplasms from benign to malignant transformation [@B48]. Anti-angiogenic therapy provides an efficient way for arresting the tumor growth through inhibiting the key angiogenic activators [@B7], [@B49]. Several AIAs have been approved by the Food and Drug Administration (FDA) for clinical cancer treatment since 2003 [@B7]. However, associated toxicities of these AIAs are nonnegligible according to the clinical/preclinical investigation, which includes hypertension, vascular contraction, regression of blood vessels and proteinuria [@B14], [@B17], [@B50].

### 2.1.1 Nano-antiangiogenesis-based cancer monotherapy {#Section2.1.1}

Compared to the free AIAs, nanomedicine could both improve their therapeutic outcomes *via* regulating their release behavior and increasing the drug accumulation in the tumor site through the enhanced permeability and retention (EPR) effect as well as actively targeting the tumor and/or endothelial cells *via* surface conjugation with target ligands [@B51], [@B52]. For example, mesoporous silica nanoparticles (MSNs) could significantly improve the targeting efficacy of tanshinone IIA (an angiogenesis inhibitor) to HIF-1*α* overexpression, leading to improved antiangiogenesis activity in a mouse colon tumor model (HT-29) [@B53]. Several over-expressed receptors, such as integrin *α*~v~*β*~3~ and Neuropilin-1, were employed as the targets of nanomedicines, which showed enhanced targeting efficacy and improved tumor inhibiting rate [@B54]-[@B56]. Furthermore, paclitaxel (PTX) loaded antiangiogenic polyglutamic acid (PGA)-PTX-E-\[c(RGDfK)~2~\] nano-scaled conjugate could markedly suppressed the growth and proliferation of the *α*~v~*β*~3~-expressing endothelial cells (ECs) and several cancer cells [@B57]. Additionally, bevacizumab, an angiogenesis inhibitor against vascular endothelial growth factor (VEGF) was directly used as a targeting ligand to modify magnetic iron oxide nanoparticles (IONPs), which was demonstrated to be an efficient platform for bevacizumab delivery in mice breast tumor (4T1) treatment [@B58].

Nanonization strategies for AIAs not only could reduce their associated toxicities and enhance the antitumor efficacy to some degree, but also provide a multidrug co-delivery platform toward enhancing the AIAs-based combination anticancer efficacy [@B31], [@B34], [@B59]-[@B61].

### 2.1.2 Synergistic antiangiogenesis/chemotherapy {#Section2.1.2}

Angiogenesis inhibitors were often used together with chemotherapeutics for overcoming their shortages and enhancing the antitumor efficacy [@B17]. Recently, types of engineered anti-angiogenic nanotherapeatics have been developed for cancer combination treatment. For instance, doxorubicin (DOX) and mitomycin C (MMC) co-loaded polymer-lipid hybrid nanoparticles could significantly increase the animal survival and tumor cure rate compared with liposomal DOX for treating multidrug resistant human mammary tumor xenografts [@B34]. DOX combining with methotrexate (MTX), which was co-delivered by MSNs could also significantly improve the efficacy of oral squamous cell carcinoma treatment through down-regulating the expression of lymph dissemination factor (VEGF-C) [@B62]. Zhu and coworkers synthesized a matrix metalloproteinase-2 (MMP-2)-responsive nanocarrier for the co-delivery of camptothecin (CPT) and sorafenib, which was demonstrated to be an efficient approach for colorectal cancer synergistic therapy [@B63]. Curcumin (Cur), a potent antiangiogenesis agent, was co-loaded with DOX into pH-responsive poly(beta-amino ester) copolymer NPs for the 4T1 tumor treatment, which showed intensive anti-angiogenic and pro-apoptotic activities [@B64].

### 2.1.3 Synergistic antiangiogenesis/gene therapy {#Section2.1.3}

The co-delivery of antiangiogenesis drugs and gene silencing agents is considered to be another efficient way for cancer starvation therapy [@B43], [@B65]-[@B67]. For example, Lima and coworkers synthesized a chlorotoxin (CTX)-conjugated liposomes for anti-miR-21 oligonucleotides delivery, which promoted the efficiency of miR-21 silencing and enhanced the antitumor activity with less systemic immunogenicity [@B68]. Liu *et al.* also found that the fusion suicide gene (yCDglyTK) could induce tumor cell apoptosis more effectively after co-delivering with VEGF siRNA by a calcium phosphate nanoparticles (CPNPs), where the density of capillary vessels was also observed to obviously decrease in the xenograft tissue of gastric carcinoma (SGC7901) [@B67]. Furthermore, the poly-VEGF siRNA/thiolated-glycol chitosan nanocomplexes were employed to help overcome the resistant problem of bevacizumab by Kim and coworkers [@B65]. The results indicated that the combination of these two VEGF inhibitors produced synergistic effects with decreased VEGF expression and drug resistance.

### 2.1.4 Synergistic antiangiogenesis/phototherapy {#Section2.1.4}

Nanomaterial-based phototherapies that can selectively kill cancer cells without normal tissue injury have attracted extensive interest in the field of cancer treatments [@B69]-[@B71]. Enhanced antitumor efficacy was also observed when angiogenesis inhibitors and phototherapy agents were combined [@B31], [@B72]. For example, Kim and coworkers developed a hybrid RNAi-based AuNP nanoscale assembly (RNAi-AuNP) for combined antiangiogenesis gene therapy and photothermal ablation **(Figure [2](#F2){ref-type="fig"})** [@B31]. AuNPs modified by single sense/anti-sense RNA strands could self-assemble into various geometrical nanoconstructs (RNAi-AuNP). Then, PEI/RNAi-AuNP complexes were prepared with branched polyethylenimine (BPEI) for the purpose of effective intracellular delivery. After intratumoral administration, the therapeutic effects of PEI/RNAi-AuNP complexes could be activated by continuous-wavelength lasers or high intensity focused ultrasound, which led to effective antiangiogenesis and tumor ablation. In another work, a carrier-free nanodrug was prepared by self-assembling of Sorafenib and chlorin e6 (Ce6) for antiangiogenesis and photodynamic therapy [@B72]. This nanodrug presented good passive targeting behavior in the tumor sites and effective reactive oxygen species (ROS) generation ability *in vivo*. The tumor inhibition rate was significantly improved after combination with Sorafenib. With additional merits, such as good biosafety and biocompatibility, this nano-integrated strategy promised potential for cancer synergetic treatment in clinic.

2.2 VDAs-based cancer starvation therapy {#Section2.2}
----------------------------------------

VDAs, as a unique class of anticancer compounds, is designed to selectively prevent the established abnormal tumor blood vasculature by targeting ECs and pericytes, leading to tumor starvation and central necrosis through hypoxia and nutrient deprivation [@B73]. However, they are powerless to the cancer cells at the tumor margin, which could draw oxygen and nutrients from the surrounding normal tissues [@B15]. Beside this, several other vascular risk factors, such as the acute coronary syndromes, blood pressure alteration, abnormal ventricular conduction, and transient flush, also limit the further application of free VDAs [@B73]. To overcome the above issues and enhance their antitumor ability, VDAs-based multimodal cancer therapies have been developed for solid tumor treatments [@B23], [@B27], [@B28], [@B42], [@B74]-[@B78].

### 2.2.1 Free VDAs-enhanced nanomedicine-based chemotherapy {#Section2.2.1}

The barriers of heterogeneity and high interstitial fluid pressure of solid tumors not only limit the targeting efficiency of nanomedicines, but also weaken their antitumor ability against the tumor central area [@B79], [@B80]. Recent studies reported that small free molecule VDAs could help nanomedicines to overcome the above drawbacks [@B42], [@B74], [@B75]. For example, Chen and coworkers developed a coadministration strategy using free CA4P and CDDP-loaded PLG-*g*-mPEG NPs (CDDP-NPs) for complementing each other\'s antitumor advantages and improving the antitumor efficiency [@B75]. The multispectral optoacoustic tomography (MSOT) images indicated that the tumor penetration of CDDP-NPs highly relied on the tumor vasculature, which aggregated in the peripheral region of the tumors. While co-administration of free CA4P and CDDP-NPs improved the tumor cellular killing efficiency both in the central and peripheral regions according to hematoxylin and eosin (H&E) staining. The enhanced antitumor efficiency against both murine colon cancer (C26) and human breast cancer (MDA-MB-435) models supported that this combination strategy was a promising way for solid tumor treatment.

Furthermore, small molecule VDAs could induce tumor target amplification of ligand-coated NPs through selectively modifying tumor vasculature. For example, protein p32, a stress-related protein which is specifically expressed on the surface of tumor cells [@B37], can selectively bind with the phage-displayed cyclic peptide (LyP-1) [@B81]. Ombrabulin, a small molecule VDAs, was used to induce the local upgraded presentation of protein p32 for enhancing the tumor "active targeting" of LyP-1 coated NPs. The *in vivo* results demonstrated that the recruitment of LyP-1 coated DOX-loaded NPs significantly increased after pretreating with ombrabulin when compared with the control groups [@B74]. In another work, coagulation-targeted polypeptide-based NPs were developed for improving their tumor-targeting accumulation by homing to VDA-induced artificial coagulation environment. The*in vivo* results showed that this cooperative targeting system recruited over 7-fold higher CDDP doses to the tumors than non-cooperative control groups [@B42]. The above cooperative targeting strategies combining with free VDAs and ligand-coated NPs showed obviously decreased tumor burden and prolonged mice survival compared to the non-cooperative controls.

### 2.2.2 VDAs-nanomedicine induced synergistic starvation/chemotherapy {#Section2.2.2}

VDAs-nanomedicine could enhance their accumulation and retention at the leaky tumor vasculature *via* EPR effect, leading to high distribution and gradual release of VDAs around the immature tumor blood vessels as well as prolonged vascular disruption effect compared to free drugs [@B28]. Beside this, nanomedicine also provides a platform for VDAs-based cancer multimodal therapy [@B23], [@B27], [@B76], [@B78]. For instance, a multi-compartmental "nanocell" integrating a DOX-PLGA conjugate core and a phospholipid shell was prepared for achieving temporal release of DOX and combretastatin A4 (CA4) [@B23]. After accumulating at the tumor site, CA4 was released from the outer phospholipid shell of the nanocell rapidly and attacked the tumor blood vessels, and DOX was then released subsequently from the inner polymeric core for killing tumor cells directly. This mechanism-based strategy exhibited reduced side toxicity and enhanced therapeutic synergism in the progress of inhibiting murine melanoma (B16F10) and Lewis lung carcinoma growth.

Furthermore, several polymer-VDA conjugates caused amplified TME characteristics was also utilized to develop new cancer co-administration strategies [@B27], [@B78]. Hypoxia is one of the major features of solid tumors which can promote neovascularization, drug resistance, cell invasion and tumor metastasis [@B82], [@B83]. Meanwhile, the existence of hypoxia also provides the desired target for tumor selective therapy [@B21]. Tirapazamine (TPZ) is a typical hypoxia-activated prodrug (HAP), which own low toxicity toward normal tissues and can selectively kill the hypoxic cells after conversion into cytotoxic benzotriazinyl (BTZ) radical within hypoxic regions [@B84]. Nevertheless, the insufficient hypoxia level within tumors tremendously limited its further clinical application [@B85]. To address this, Chen and coworkers proposed a cooperative strategy based on VDA-nanomedicine and HAPs for solid tumor treatment**(Figure [3](#F3){ref-type="fig"})** [@B27]. In this study, poly(L-glutamic acid)-CA4 conjugate nanoparticles (CA4-NPs) were employed to selectively disrupt the abnormal vasculature of the tumor, as well as elevating the hypoxia level of the tumor microenvironment (TME). The intensive hypoxic TME further boosted the antitumor efficacy of TPZ subsequently. The *in vivo* results demonstrated that this combinational strategy can not only completely suppress the small tumor growth (initial tumor volume: 180 mm^3^), but also obviously keep down the size of large tumors (initial tumor volume: 500 mm^3^) without distal tumor metastasis. Moreover, Chen and coworkers also demonstrated that the expression of matrix metalloproteinase 9 (MMP9, a typical tumor-associated enzyme) in treated tumors (4T1) could be markedly increased by more than 5-fold after treatment with CA4-NPs. These overexpressed MMP9 could further activate the DOX release from a MMP9-sensitive doxorubicin prodrug (MMP9-DOX-NPs) and enhance the *in vivo* cooperative antitumor efficacy [@B78].

2.3 Vascular blockade-induced cancer starvation therapy {#Section2.3}
-------------------------------------------------------

Besides the strategies of anti-angiogenic therapy and VDAs-induced tumor blood vessel disrupting, another promising strategy for cancer starvation therapy was proposed by shutting off the blood supply with nanothereapeutics that could selectively blockade tumor vascular and then inducing tumor necrosis.

### 2.3.1 Tumor-homing peptides-induced cancer starvation therapy {#Section2.3.1}

Tumor-homing peptides (THPs), such as pentapeptide (CREKA) and 9-amino acid cyclic peptide (CLT-1), could specially bind with fibrin-fibronectin complex in tumor blood clots [@B86]. Based on this, Ruoslahti and coworkers developed a CREKA modified IONPs for fibrin-fibronectin complexes targeting and subtle clotting in tumor vessels [@B87]. The initial deposition of these CREKA-IONPs created new binding sites for the subsequent NPs, and further enhanced the blood coagulation in the tumor lesion. The results indicated that the tumor imaging efficiency of this self-amplifying tumor homing system owned about six-fold enhancement compared to the control groups. However, the tumor inhibition efficiency of this system showed no significant improvement due to the insufficient tumor vessel occlusion. To this end, a cooperative theranostic system containing CREKA-IONPs and CRKDKC-coated iron oxide nanoworms was further developed by the same research group for improving the clots binding efficacy. The results proved that this combination system led to 60\~ 70% tumor blood blockades and obvious tumor size reduction*in vivo* [@B88].

### 2.3.2 Thrombin-mediated cancer starvation therapy {#Section2.3.2}

Thrombin is a serine protease that catalyzes series of coagulation-related reactions and leads to rapid thrombus formation during the clotting process [@B48]. If thrombin can be precisely delivered to the tumor site and lead to selective occlusion of tumor-associated vessels by inducing the local blood coagulation, it might be a promising way for inhibiting the growth and metastasis of tumors. Recently, a nucleolin-targeting multifunctional DNA nanorobotic system was constructed for smart drug delivery. The presence of the nucleolin subsequently triggered the opening of these DNA nanotubes and released the loaded therapeutic thrombin, which then led to specific intravascular thrombosis and tumor vessel blockade at the tumor site [@B26]. The growth of several tumor models was suppressed efficiently after treating with this thrombin-loaded DNA nanorobot, demonstrating that this system could become an attractive platform for cancer starvation therapy in a precise manner.

### 2.3.3 Deoxygenation agent-induced cancer starvation therapy {#Section2.3.3}

It is known that insufficient oxygen (O~2~) supply could result in hypoxia-induced tumor cell necrosis [@B89]. Based on this, Zhang *et al.* designed an injectable polyvinyl pyrrolidone (PVP)-modified magnesium silicide (Mg~2~Si) nanoparticle as a nano-deoxygenation agent (nano-DOA) for directly consuming the intratumoral O~2~ and starving tumors [@B11]. This polymer-coated Mg~2~Si NPs could respond to the slightly acidic TME after the intratumoral injection, and be converted into silicon dioxide (SiO~2~) by scavenging the surrounding O~2~ at the tumor site. As a byproduct, the *in situ* formed SiO~2~ aggregates further occluded the tumor capillaries and obstructed the follow-up nutrient and O~2~ supply.

On the other hand, the intratumoral hypoxic level was also enhanced in the progress of O~2~ consuming with the presence of DOA. Given this reason, Bu and coworkers prepared a TPZ loaded PVP-modified Mg~2~Si nanoparticles (TPZ-MNPs) for drug delivery and combination cancer therapy [@B38]. After intratumoral injection, the TPZ-MNPs quickly scavenged the O~2~ *in situ* and created an artificial anaerobic environment which caused the surrounding cell dormancy. Meanwhile, the released TPZ was activated in this promoted hypoxia TME, which further caused the now-dormant tumor cells death.

2.4 GOx-mediated cancer starvation therapy {#Section2.4}
------------------------------------------

Glucose is the major energy supplier for tumor growth and proliferation [@B90]. Glucose oxidase (GOx) can specifically catalyze the conversion of glucose into gluconic acid and hydrogen peroxide (H~2~O~2~) with the involvement of O~2~. This reaction can directly consume glucose and O~2~, and elevate the local acidity, hypoxia and oxidation stress*in vivo*. Given this background, GOx has aroused considerable interest for cancer diagnosis and treatment in the past decade [@B4], [@B91]. Nevertheless, there are several limitations of this approach when using GOx as an anticancer agent. On the one hand, the overproduced H~2~O~2~ of glucose oxidation can cause systemic toxicity and lethal chain reactions through directly damaging cell membranes, proteins and DNA of normal cells [@B92], [@B93]. On the other hand, similar glucose supply and physiological requirement of normal cells often lead to off-targeting and ineffective starvation treatment [@B94]. Through nanomedicine, GOx can co-delivery with other therapeutic agents for cancer multimodal treatments [@B4]. Herein, we overview the recent representative GOx-based nanomedicines for cancer starvation therapy.

### 2.4.1 GOx-based cancer monotherapy {#Section2.4.1}

GOx could be used as an antitumor agent alone through consuming the intratumoral glucose and making the tumor "starving". The continuously generated H~2~O~2~ could further lead to DNA damage and tumor cell apoptosis [@B95], [@B96]. For example, Dinda *et al.* prepared a GOx-entrapped biotinylated vesicle for active targeting cancer starvation therapy [@B97]. This GOx-containing system showed about six-fold higher tumor cell killing efficiency compared to normal cells through depleting the glucose supply for tumor cells *in vitro*. However, the glucose depletion efficiency was restrained by the hypoxic TME *in vivo*, because of the insufficient O~2~ supply in the solid tumor. Therefore, a hyaluronic acid (HA)-coated GOx and MnO~2~ coloaded nanosystem (GOx-MnO~2~\@HA) was constructed for enhancing cancer starvation therapy outcome [@B98]. After uptaking by the CD44-expressing tumor cells, the local glucose was converted into gluconic acid and H~2~O~2~ with GOx catalysis. The generated H~2~O~2~ then reacted with MnO~2~ to generate O~2~, which further accelerated the local glucose-consumption. This nanosystem provided benefit to break the hypoxia obstacles and enhance the antitumor effect by GOx.

### 2.4.2 Synergistic starvation/chemotherapy {#Section2.4.2}

As discussed above, the concentration of generated H~2~O~2~ can be substantially elevated in the presence of GOx at the lesion site. The increased H~2~O~2~ level was exquisitely used to active the H~2~O~2~-sensitive prodrugs for enhancing the synergistic efficiency of both cancer starvation and chemotherapy [@B41], [@B99]. For example, Li *et al.* prepared a pH-responsive prodrug-based polymersome nanoreactor (GOx\@PCPT-NR) that consisted of piperidine group, camptothecin (CPT) prodrug, PEG and GOx for cancer combination therapy **(Figure [4](#F4){ref-type="fig"})** [@B41]. This polymersome nanoreactor owned prolonged blood circulation and high tumor accumulation efficiency. The terminal elimination half-life of GOx\@PCPT-NR reached above 39 hours after intravenous injection. This drug delivery system also showed excellent stability and almost no H~2~O~2~ and free CPT were found within 48 h treatment in the plasma or liver. Nevertheless, the slight acidity of the tumor (pH = 6.8) could trigger the GOx release from the polymersome, which then catalyzed the conversion of intratumoral glucose into gluconic acid and H~2~O~2~. The enhanced acidity causing by the generated gluconic acid could further promote the GOx release, while the elevated H~2~O~2~ level could further accelerate the active CPT release. The accumulating effects amplified the combination antitumor efficiency [@B41]. Furthermore, this strategy was further confirmed by another biomimetic cascade nanoreactor (Mem\@GOx\@ZIF-8\@BDOX) *in vivo*. As a byproduct of GOx-induced glucose depletion, gluconic acid could promote the release of loaded BDOX prodrug from the nano-framework, and the released BDOX were then converted into DOX in the presence of elevated H~2~O~2~ at the tumor site [@B99].

### 2.4.3 GOx-inducing cancer starvation and hypoxia-activated chemotherapy {#Section2.4.3}

The consummation of molecular oxygen could increase the local hypoxia level in the progress of GOx-involved cancer therapy. This promoted hypoxic microenvironment was also employed to activate the hypoxia-activated prodrugs and amplify their antitumor activity [@B13], [@B30], [@B33], [@B100]. For example, a MOF-based biomimetic nanoreactor coating with erythrocyte membrane (eM) was developed for precise GOx and TPZ delivery and cancer combination therapy **(Figure [5](#F5){ref-type="fig"})** [@B13]. The grafted biomimetic surface of the nanoreactor not only endowed it with prolonged blood circulation and immune-escaping property, but also enhanced the tumor homing efficiency of this nanosystem. After uptake by cells, the released GOx deprived the endogenous glucose and O~2~, which resulted in amplified hypoxic microenvironment and sufficient activation of TPZ. Based on the above synergistic cascade effects, a colon cancer model were efficiently inhibited *in vivo*. In another work, the PEG-modified long-circulating liposomes were used to sequentially deliver GOx and banoxantrone dihydrochloride (AQ4N, a hypoxia-activated prodrug) to tumors for cancer combination starvation/chemotherapy [@B30]. The*in vivo* photoacoustic image indicated that GOx-loaded liposome could obviously deplete the glucose of the tumor site, and lead to tumorous hypoxia enhancement. Under the elevated hypoxic microenvironment, the antitumor activity of the subsequent arrival liposome-AQ4N was activated by reducing low toxic AQ4N into high toxic 1,4-Bis\[\[2-(dimethylamino)ethyl\]amino\]-5,8-dihydroxyanthracene-9,10-dione (AQ4) by the series of intracellular reductases. Synergistically enhanced antitumor effect was observed on 4T1 murine breast cancer model after treating with this liposome-based GOx/AQ4N co-delivery system. These results demonstrated that combination of GOx-based cancer starvation therapy and HAP-involved hypoxia-activated chemotherapy is an effective way for solid tumor treatment.

Furthermore, in order to reduce the systemic toxicity, Wang and coworkers developed a nanoclustered cascaded enzymes by crosslinking GOx and CAT with a pH-responsive block polymer poly(ethylene glycol)-*block*-poly(2-hydroxyethyl methacrylate) bearing 2-(2-carboxyethyl)-3-methylmaleic anhydride (PEG-*b*-PHEMA~CMA~) with a BSA/BSA~TPZ~ (wt:wt, 1:2) outer shell for cancer starvation and hypoxia-activated chemotherapy [@B94]. The experimental data indicated that GOx and CAT could be released by the stimuli of the mild acidic TME after accumulating at the tumor site. Then, the release rate was self-accelerated by the subsequent generated gluconic acid with GOx-induced glucose consumption. Meanwhile, the aggravated hypoxia of TME further activated the BSA~TPZ~ which led to hypoxia-activated chemotherapy. Importantly, the authors also found that the present CAT could timely eliminate the appeared H~2~O~2~ as well as lowered the systemic toxicity of GOx-mediated cancer starvation therapy.

### 2.4.4 Starvation/oxidation synergistic therapy {#Section2.4.4}

Glutathione (GSH) is a natural antioxidant in the body, which prevents the damage of important cellular components by ROS, such as H~2~O~2~, hydroxyl radicals (∙OH), and singlet oxygen (^1^O~2~). However, GSH could weaken the antitumor efficiency in the progress of ROS-mediated cancer therapy. To this end, Li *et al.* prepared GOx-loaded therapeutic vesicles based on a diblock copolymer containing a mPEG segment and copolymerized piperidine-functionalized methacrylate and phenylboronic ester (mPEG-*b*-P(PBEM-*co*-PEM)) [@B101]. After precise activation at the tumor site, the GOx-induced enzymatic reaction caused local consumption of glucose and O~2~ and generation of gluconic acid and H~2~O~2~. The generated H~2~O~2~ not only elevated the intracellular oxidative stress, but also led to the production of quinone methide (QM), which further suppressed the antioxidant ability of the tumor cells through depleting the intracellular GSH. These cumulative anticancer effects of the therapeutic vesicles resulted in effective cancer cell death and tumor ablation.

H~2~O~2~ can be transformed into the highly toxic ROS under certain conditions *in vivo* [@B71], [@B102]. For example, H~2~O~2~ could be disproportionated into ∙OH with the presence of Fenton reaction catalysts under acidic condition [@B103], [@B104]. While, in the presence of neutrophil-expressed phagocytic enzyme myeloperoxidase (MPO), H~2~O~2~ and chlorine ion (Cl^-^) could be converted into hypochlorous acid (HClO) through the enzymatic reaction [@B105]. Based on this, specific strategies were developed to combine with GOx for cancer starvation/oxidation synergistic therapy [@B106]-[@B110].

In a recent study, Huo *et al.* designed a dendritic silica nanoparticle-based sequential nanocatalyst for co-delivering of GOx and Fe~3~O~4~ NPs (GOx-Fe~3~O~4~\@DMSNs) for enhancing of combination anticancer efficiency **(Figure [6](#F6){ref-type="fig"})** [@B106]. After EPR effect-induced accumulation of these nanocatalysts in the tumor site, the released GOx catalyzed the oxidation of the intratumoral glucose to gluconic acid and H~2~O~2~ and led to tumor starvation and central necrosis. Thereafter, the generated H~2~O~2~ sequentially were translated into highly toxic ∙OH by Fe~3~O~4~ NPs under the slightly acidic TME, which resulted in elevated oxidative stress and massive apoptosis of tumor cells. The final tumor inhibition rate of this nanomedicine by intravenous and intratumoral treatments with the same treating dose was reached to 64.7% and 68.9%, respectively. Besides this, another core-shell TME-responsive nanocatalyst, incorporated with a magnetic nanoparticle core of iron carbide (Fe~5~C~2~)-GOx and MnO~2~-nanoshell, was constructed by Lin and co-workers [@B107]. After endocytosis by tumor cells, the MnO~2~-nanoshell of this nanosystem was degraded into Mn^2+^ and O~2~ and resulted in GOx release under the stimuli of the acidic microenvironment. The generated O~2~ could enhance consumption of the local glucose with the presence of GOx, leading to sufficient tumor starving. Sequentially, the produced H~2~O~2~ further evolved into ∙OH catalyzed by Fe~5~C~2~, resulting in efficient tumor cell death. Recently, a smart autocatalytic Fenton nanosystem, consisted of GOx-loaded zeolitic imidazolate framework (ZIF) and adenosine triphosphate (ATP)-responsive metal polyphenol network (MPN) shell, was designed by Zhang *et al*. for the combination cancer therapy [@B108]. In tumor cells, the MPN shell was degraded into Fe^3+^ and tannic acid (TA) and further trigged the inner GOx release under the stimuli of the overexpressed ATP. Then, the exposed GOx led to endogenous glucose consumption and H~2~O~2~ accumulation. With the presence of TA, the transition efficiency of Fe^3+^ to Fe^2+^ was accelerated, which further promoted the transformation of the generated H~2~O~2~ into high toxic ∙OH by Fenton reaction. These accumulating antitumor effects significantly suppressed the tumor growth.

Silver (Ag) ions have been demonstrated to kill different types of cancer cells through increasing the intracellular oxidative stress, causing mitochondrial damage, and inducing cell autophagy [@B111], [@B112]. Based on this, Huang and coworkers designed a GOx-conjugated silver nanocube (AgNC-GOx) for efficient Ag ions delivery and synergistic starvation/metal-ion therapy [@B113]. AgNC-GOx catalyzed the glucose conversion into gluconic acid and H~2~O~2~ after uptake by the tumor cells. Cumulative gluconic acid elevated the acidity of TME which accelerated the AgNC degradation and Ag ions generation in the tumor site. Meanwhile, the generated H~2~O~2~ and Ag ions were found to lead the eradication of 4T1 cancer cells. Both the glucose consumption and accumulation of toxic H~2~O~2~ and Ag ions significantly suppressed the tumor growth and prolonged the mice survival.

HClO is a powerful ROS which can be generated by the MPO-mediated catalysis and owns higher cellular toxicity in comparison with H~2~O~2~. It has been proved to be a promising candidate for cancer therapy through disrupting some cellular functions and promoting the tumor cell death by the oxidation progress [@B114]. Given this pattern, Zhang and coworkers prepared an "artificial neutrophils", consisting of GOx and chloroperoxidase (CPO) coloaded zeolitic imidazolate framework-8 (ZIF-8) core and neutrophil membrane (NM) coating (GOx-CPO\@ZIF-8\@NM), for both of cancer and infection treatments. NM coating help the NPs to target the tumor site efficiently **(Figure [7](#F7){ref-type="fig"})** [@B109]. After uptake by the tumor cells, the embedded GOx and CPO were released from the ZIF-8 NPs, which synergistically enhanced the glucose depletion and HClO generation through a sequential enzymatic catalysis progress. According to the results, this artificial neutrophil can produced seven-fold higher reactive HClO than the natural neutrophils both *in vitro* and *in vivo*. Benefit from this, 4T1 tumors of mice was almost completely eradicated after treating with this neutrophil-mimicking NPs.

### 2.4.5 Synergistic starvation/phototherapy {#Section2.4.5}

Blue light irradiation (450\~490 nm) could promote the Conversion of H~2~O~2~ into more toxic ∙OH, which provides an alternative approach for cancer therapy. However, insufficient H~2~O~2~ supplies in the tumor site weaken the ∙OH production as well as the antitumor efficiency. Instead, GOx, as an antitumor agent, could induce the glucose depletion and tumor starvation with consecutively generating of H~2~O~2~. Given this fact, Chang *et al.* developed GOx-conjugated polymer dots (Pdot-GOx) for enzyme-enhanced phototherapy (EEPT) [@B115]. After immobilizing into tumor, Pdot-GOx NPs could efficiently catalyze the glucose oxidation and steadily produce H~2~O~2~, which led to the enhancement of the local oxidative stress. Meanwhile, the appeared H~2~O~2~ could also be photolyzed to produce ∙OH under light irradiation (460 nm) for killing tumor cells. The experimental results indicated that this EEPT strategy exhibited much higher efficacy in inhibiting MCF-7 tumor growth compared with the control groups in mouse models.

Photodynamic therapy (PDT) has proved to be a promising platform in imaging and treatment of cancers and other diseases [@B116]. As a noninvasive method, PDT utilizes the generated toxic ROS to destroy the cellular organelles and ablate tumors with the presence of photosensitizers under light irradiation. However, the poor penetration of the excitation light makes it powerless against deeply seated tumors [@B117]. Besides, hypoxia of TME is another suppressive factor for this O~2~-dependent antitumor approach [@B118]. Thus, the combination with other strategies would be an alternative way for improving the efficiency of PDT-involved cancer therapy [@B119], [@B120]. Recently, Li *et al*. developed a GOx and catalase co-loaded porphyrin metal-organic framework with tumor cell membrane surface coating (mCGP) for synergistic starvation/PDT therapy. This mCGP NPs owned excellent tumor homing ability due to the tumor cell membrane surface coating. After internalized by tumor cells, the loaded catalase in mCGP was found to catalyze the generated H~2~O~2~ to disproportionate into molecular O~2~ and H~2~O, accelerating the consumption of endogenous glucose and promoting the production of ^1^O~2~ under light irradiation. These accumulating effects obviously enhanced the *in vivo* synergistic antitumor efficiency of mCGP NPs. In another work, Yu *et al*. developed a biomimetic nanoreactor (bioNR)-based starvation/PDT strategy for effective combating deeply seated metastatic tumors [@B32]. The bioNR was constructed based on a GOx and Ce6 conjugated hollow mesoporous silica NPs (HMSNs) with B16F10 cell membrane coating, which was filled with bis\[2,4,5-trichloro-6-(pentyloxycarbonyl)phenyl\]oxalate (CPPO) and perfluorohexane (PFC) in the cavity. After homing to the tumor, the peripheral glucose was converted into gluconic acid with H~2~O~2~. At the same time, the appeared H~2~O~2~ not only promoted the local oxidative stress of the tumor, but also could react with CPPO to generate chemical energy, which led to chemiluminescence resonance energy transfer-based PDT with the presence of Ce6. Furthermore, the molecular oxygen releases from PFC further increase the antitumor efficiency of O~2~-dependent GOx-involved cancer starvation therapy and PDT. It was demonstrated that the Ce6-induced PDT effect for tumor metastasis was substantially enhanced after combination with GOx-involved cancer starvation therapy.

As described above, insufficient oxygen supply in solid tumors could limit the antitumor efficiency of GOx-related therapeutics. To address this challenge, Cai and coauthors prepared a HA-conjugated porous hollow Prussian Blue NPs (PHPBNs) for facilitating GOx delivery and tumor synergistic starvation/photothermal therapy [@B121]. The HA shell could enhance the targeting efficiency towards CD44 overexpressing tumors. After cellular endocytosis, the released GOx catalyzed the glucose depletion by consuming O~2~, and PHPBNs sequentially catalyzed the generated H~2~O~2~ splitting into O~2~ and H~2~O to amplify the tumor starvation effect. Furthermore, GOx-induced glucose depletion not only inhibited the tumor growth, but also suppressed the expression of heat shock proteins (HSPs), where the latter facilitated PHPBNs-mediated low-temperature photothermal treatment to reduce their resistance. The results indicated that this combinational therapeutic system could significantly repress tumor growth in mice. In another work, Tang *et al*. developed a novel BSA-directed two-dimensional (2D) MnO~2~ nanosheet (M-NS) by one-step method [@B122]. This M-NS not only owned an excellent GOx-like activity for catalyzing the local glucose oxidation, but also exhibited high photothermal conversion efficiency due to the large surface area. Furthermore, this M-NS artificial enzyme showed higher thermal stability than natural GOx. The experimental results indicated that the M-NS-induced intratumoral glucose depletion inhibited the ATP production as well as cellular HSPs expression, which promoted the sensitivity of tumors to the M-NS-mediated photothermal treatments.

### 2.4.6 Starvation/gas synergistic therapy {#Section2.4.6}

Previous studies have demonstrated that nitric oxide (NO) could be used as a therapeutic gas for cancer therapy through the nitrosation of mitochondria and DNA or enhance the efficiency of PDT or radiation therapy[@B123], [@B124]. L-Arginine (L-Arg) is a natural NO donor which can release NO in the presence of inducible NO synthase enzyme (iNOS) or in the presence of H~2~O~2~ [@B125], [@B126]. Given this reality, Fan *et al*. employed a hollow mesoporous organosilica nanoparticle (HMON) for GOx and L-Arginine co-delivery (L-Arg-HMON-GOx) and cancer starvation/gas therapy **(Figure [8](#F8){ref-type="fig"})** [@B46]. After accumulating at the tumor site, the intratumoral glucose was transformed into gluconic acid and H~2~O~2~ by GOx. The generated H~2~O~2~ not only killed the tumor cells directly, but also enhanced the gas therapy effect through oxidizing L-Arginine into NO in the acidic TME. The *in vivo* experimental results indicated that L-Arg-HMON-GOx treated U87MG tumor bearing mice have the best tumor ablation outcome and much longer survival rate than the control groups, indicating the significantly promoted synergistic starvation/gas therapy effects.

### 2.4.7 GOx-mediated starvation/immunotherapy {#Section2.4.7}

Although cancer immune checkpoint blockade (ICB) therapy has been witnessed exciting progress in treating many types of cancers in clinic, several remaining challenges still need to be overcome in ICB-related cancer immunotherapy, such as low immune response efficacy, off-target side effects, and immune suppressive factors in TME [@B127]-[@B131]. Combination of cancer immunotherapy with other anticancer methods has been considered as an efficient strategy for addressing these issues [@B132]-[@B138]. For example, Xie *et al*. presented a therapeutic method combing with cancer cell membrane coated GOx-loaded mesoporous silica nanoparticles (CMSN-GOx) and anti-programmed cell death protein 1 (anti-PD-1) for cancer starvation/immunotherapy **(Figure [9](#F9){ref-type="fig"})** [@B47]. Contributing to the CM coating, CMSN-GOx was efficiently delivered to the tumor site. The released GOx could not only catalyze the glucose depletion to inhibit the tumor growth, but also induce more dendritic cells (DCs) maturation which further enhanced the antitumor efficacy of anti-PD-1.*In vivo* experimental results indicated that CMSN-GOx plus anti-PD-1 combination treatment provided more effective tumor suppression than any single therapies.

### 2.4.8 GOx-involved multimodal synergistic therapy {#Section2.4.8}

As previously reported, H~2~O~2~ generated in the GOx-induced glucose oxidation could split into high toxic ∙OH radicals through Fenton reaction in the presence of Fe~3~O~4~[@B106]. The rising tumor temperature could further elevate the conversion efficiency of local H~2~O~2~ to ∙OH as well as enhance the antitumor ablation [@B71]. Given this fact, Feng *et al*. developed a Fe~3~O~4~/GOx co-loaded polypyrrole (PPy)-based composite nanocatalyst (Fe~3~O~4~\@PPy\@GOx NC) for multimodal cancer therapy. Fe~3~O~4~\@PPy\@GOx NCs could selectively accumulate at the tumor site (4T1) *via* EPR effect. Thereafter, the released GOx-mediated intratumoral glucose oxidation elevated the H~2~O~2~ level and acidity of TME, which sequentially resulted in local ∙OH accumulation and tumor cell death. At the same time, the polypyrrole (PPy) component which owned a high photothermal-conversion efficiency (66.4% in NIR-II biowindow) considerably increased the tumor temperature in both in NIR-I and NIR-II biowindows, which accelerated the H~2~O~2~ disproportionation as well as enhanced the photothermal-enhanced cancer starvation/oxidation therapy.

2.5 Other strategies for cancer starvation therapy {#Section2.5}
--------------------------------------------------

Recently, types of special strategies in this field, which aimed at some critical nutrients, such as lactate and cholesterol, were also developed [@B39], [@B40], [@B139]-[@B141].

Lactate, which was once considered to be the waste product of glycolysis, has been demonstrated that can "fuel" the oxidative tumor cells growth as an energy substrate [@B12], [@B142]. Investigation indicated that interfering the lactate-fueled respiration could selectively kill the hypoxic tumor cells *via* inhibiting the expression of lactate-proton symporter, monocarboxylate transporter 1 (MCT1) [@B143]. Meanwhile, the reduction of lactate uptake by inhibiting the expression of MCT1 could transform the lactate-fueled aerobic respiration to anaerobic glycolysis as well as lower the O~2~ consumption in tumor cells which would facilitate the O~2~-depleting cancer therapy. For example, Zhang and coworkers developed an *α*-cyano-4-hydroxycinnamate (CHC) loaded porous Zr (IV)-based porphyrinic metal-organic framework (PZM) NPs with HA coating for cancer combination therapy **(Figure [10](#F10){ref-type="fig"})** [@B40]. After effectively accumulating at the CT26 tumors, the released CHC could obviously decrease the expression of MCT1 and turn down the lactate uptake which leading to lower the O~2~ consumption. As a result, the PDT efficiency was markedly enhanced due to the sufficient ^3^O~2~ converting upon the laser irradiation (600 nm). Additionally, reducing the production of lactate *via* knockdown of lactate dehydrogenase A (LDHA) in tumor cells was also demonstrated that could neutralize of the tumor acidity and enhance the anti-PD-L1-mediated immunotherapy [@B139].

Recently, Thaxton and coworkers designed synthetic high density lipoprotein nanoparticles (HDL-NPs) with gold NPs as a size- and shape-restrictive template for lymphoma starvation therapy [@B39]. This HDL-NPs could specially target scavenger receptor type B-1 (SR-B1), which is a high-affinity HDL receptor expressed by lymphoma cells. This combination of SR-B1 promoted the cellular cholesterol efflux and limited the cholesterol delivery, which selectively induced cholesterol starvation and cell apoptosis. The B-cell lymphoma growth was obviously inhibited after HDL-NPs treatment of B-cell lymphoma bearing mice. Furthermore, this HDL-NPs could reduce the activity of myeloid-derived suppressor cells (MDSCs), a type of innate immune cells that potently inhibit T cells, through specifically binding with SR-B1of MDSCs [@B140]. In Lewis lung carcinoma mice model, the *in vivo* data showed that the suppression of MDSCs by HDL-NPs markedly increased CD8^+^ T cells and reduced Treg cells in the metastatic TME. After treating with HDL-NPs, the tumor growth and metastatic tumor burden were obviously reduced and the survival rate was clearly improved due to enhanced adaptive immunity.

3. Conclusion and outlook {#Section3}
=========================

As an attractive strategy for cancer treatment, nanomedicine-mediated cancer starvation therapy could selectively deprive the nutrients and oxygen supply through antiangiogenesis treatment, tumor vascular disrupting or blockade, direct depletion of the intratumoral glucose and oxygen, and other processes. Moreover, by combining with chemotherapeutic drugs, therapeutic genes, enzymes, metal NPs, hypoxia-activated prodrugs, inorganic NPs, Fenton-reaction catalysts, photosensitizers, or photothermal agents, two or more therapeutic agents could be readily integrated into one single formulation, leading to enhanced treatment outcomes (**Table [1](#T1){ref-type="table"}**).

However, most innovations in this field are still in their infancy, with underlying challenges regarding clinical translation that need to be assessed in detail. For example, the biosafety of these nanomaterials is still significantly concerned, especially for the non-biodegradable formulations. Although the biosafety assessment of these materials could be systematically evaluated through animal models, long-term internal metabolic behaviors and related toxicity should be thoroughly investigated before clinical application. Another major concern is the aggravating hypoxia level that may accelerate the tumor invasion and metastasis in the progress of tumor starvation therapy. Detailed studies should be performed to confirm whether cancer starvation therapy could turn on the tumor metastasis switch by elevating the hypoxic TME, which would also help to develop new combination strategies for offering synergistic effects. Moreover, in addition to elevating the hypoxia level, these cancer starvation-based methods could also increase the intratumoral acidity and/or promoting the intracellular oxidative stress. It remains unknown how these changes influence the local and systemic immune responses. The advances in cancer immunotherapy would offer new insights and perspectives for further evolving cancer starvation-based treatments [@B144].

4. Abbreviations {#Section4}
================
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![Schematic illustration of nanomedicine-mediated cancer starvation therapy. AIA: angiogenesis inhibiting agent; Nano-DOA: nano-deoxygenation agent; HAP: hypoxia-activated prodrug; NO: nitric oxide; NC: nanocatalyst; PDT: photodynamic therapy; PTT: photothermal therapy; ROS: reactive oxygen species; THP: tumor-homing peptide; VDA: vascular disrupting agent.](thnov09p8026g001){#F1}

![Schematic illustration of antisense- and sense-RNA strands introduction (A), RNA-AuNP building blocks with n-designated numbers of RNA strands (B) and versatile RNAi-AuNP nanoconstructs (C). Illustration of PEI/RNAi-AUNPs-induced the combinational strategy of anti-angiogenesis/photothermal cancer therapy (D). Reproduced with permission from ref. [@B31]. Copyright 2017, Ivyspring international publisher.](thnov09p8026g002){#F2}

![Schematic illustration of hypoxia-inducing VDA nanodrug combined with hypoxia-activated prodrug for cancer therapy (A). Tumor volume changes of BALB/c mice bearing 4T1 tumors with both moderate sizes (≈180 mm^3^) (n=6). (B). and large sizes (≈500 mm^3^) (n=6). (C). All data points are presented as mean ± standard deviation (s.d.). (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001). Reproduced with permission from ref. [@B27]. Copyright 2019, Wiley-VCH.](thnov09p8026g003){#F3}

![Schematic illustration of the preparation of GOx\@PCPT-NR (A). Scheme of cancer starvation/chemotherapy *via in situ* H~2~O~2~ generation and acidity-activated CPT release (B). Molecular mechanism of GOx\@PCPT-NR-induced cancer starvation/chemotherapy (C). Reproduced with permission from ref. [@B41]. Copyright 2017, American Chemical Society.](thnov09p8026g004){#F4}

![Schematic illustration of preparation of GOx and TPZ coloaded biomimetic nanoreactor with erythrocyte membrane coating (TGZ\@eM) (A). TGZ\@eM nanoreactor induced cancer starvation/hypoxia-activated chemotherapy (B). Reproduced with permission from ref. [@B13]. Copyright 2018, American Chemical Society.](thnov09p8026g005){#F5}

![Synthetic procedure for preparation of GOx-Fe~3~O~4~\@DMSNs (A). Scheme of GOx-Fe~3~O~4~\@DMSNs induced sequential catalytic-therapeutic mechanism for cancer therapy (B). Reproduced with permission from ref. [@B106]. Copyright 2017, Nature Publishing Group.](thnov09p8026g006){#F6}

![Schematic representation of the synthesis of GOx and CPO-coloaded ZIF-8 NPs. Glucose conversation and HClO generation with the catalyzing of GOx and CPO (A). Preparation of the "artificial neutrophils" by the surface modification of the GOx/CPO-coloaded ZIF-8 NPs with natural neutrophil membrane (B). Compare to natural neutrophils, the "artificial neutrophils" showed stronger HClO generation ability for biomedical applications (C). The mechanism of enzymatic reaction of GOx, CPO and "artificial neutrophils" (D). Reproduced with permission from ref. [@B109]. Copyright 2019, Wiley-VCH.](thnov09p8026g007){#F7}

![The schematic illustration of the preparation of L-Arg-HMON-GOx for cancer starvation/gas synergistic therapy (A). Tumor volume changes (B) and survival curves (C) of U87 tumor bearing mice after different treatments (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001). Reproduced with permission from ref. [@B46]. Copyright 2017, Wiley-VCH.](thnov09p8026g008){#F8}

![Schematic illustration of CMSN-GOx induced cancer starvation/immunotherapy (A). Tumor volume changes (n=5). (B). and survival curves (n=5). (C). Of B16F10 tumor bearing mice after different treatments. All data points are presented as mean ± standard deviation (s.d.). (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001). Reproduced with permission from ref. [@B47]. Copyright 2019, American Chemical Society.](thnov09p8026g009){#F9}

![Schematic illustration of porphyrinic MOF nanoplatform mediated suppressing lactate-fueled respiration for enhanced PDT therapy (A). Tumor volume changes (n=5). (B). and body weight curves (n=5). (C). Of CT26 tumor bearing mice after different treatments. All data points are presented as mean ± standard deviation (s.d.). (\*\*\**P*\<0.001). Reproduced with permission from ref. [@B40]. Copyright 2018, Wiley-VCH.](thnov09p8026g010){#F10}
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Representative formulations for nanomedicine-mediated cancer starvation therapy described in this review.

  Strategies                                                   Materials                                                       Therapeutics                                                  Administration route                                             Treatments                                                                          Tumor models                 Ref.
  ------------------------------------------------------------ --------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------- ---------------------------- ---------
  Antiangiogenesis-related cancer starvation therapy           *α*~v~*β*~3~-integrin targeted perfluorocarbon NPs              Docetaxel-prodrug                                             *i.v.* injection                                                 Antiangiogenesis therapy                                                            Vx2 tumor bearing rabbits    [@B54]
  Chitosan NPs                                                 Ursolic acid                                                    Oral administration                                           Antiangiogenesis therapy                                         H22 tumor bearing mice                                                              [@B145]                      
  PGA-PTX-E-\[c(RGDfK)~2~\]                                    PTX                                                             *i.v.* injection                                              Antiangiogenesis therapy                                         4T1 tumor bearing mice                                                              [@B57]                       
  Recombinant human endostatin conjugated AuNPs                Recombinant human endostatin                                    Subcutaneous injection                                        Antiangiogenesis therapy                                         SW620 tumor bearing mice                                                            [@B146]                      
  MSNs                                                         Tanshinone IIA                                                  *i.v.* injection                                              Antiangiogenesis therapy                                         HT-29 tumor bearing mice                                                            [@B53]                       
  M-MSN\@PEI-PEG-KALA NPs                                      anti-VEGF siRNA                                                 *i.v.* injection                                              Antiangiogenic gene therapy                                      A549 tumor bearing mice                                                             [@B43]                       
  *α*~v~*β*~3~-integrin-targeted lipid-encapsulated NPs        Fumagillin prodrug and zoledronic acid                          *i.v.* injection                                              Dual antiangiogenic therapy                                      Vx2 tumor bearing rabbits                                                           [@B55]                       
  Thiolated-glycol chitosan formed NPs                         Bevacizumab and poly- anti-VEGF siRNA                           *i.v.* injection                                              Dual antiangiogenic therapy                                      A431 tumor bearing mice                                                             [@B65]                       
  Polymer-lipid hybrid NPs                                     DOX and MMC                                                     *i.v.* injection                                              Antiangiogenesis therapy and chemotherapy                        MDA-MB 435/LCC6/WT tumor bearing mice and MDA-MB 435/LCC6/MDR1 tumor bearing mice   [@B34]                       
  pH and thermo-responsive MSNs                                DOX and MTX                                                     *i.v.* or oral administration                                 Antiangiogenesis therapy and chemotherapy                        OSCC tumor bearing mice                                                             [@B62]                       
  PEGylated lipid bilayer-supported MSNs                       AXT and CST                                                     *i.v.* injection                                              Antiangiogenesis therapy and chemotherapy                        SCC7 tumor bearing mice                                                             [@B147]                      
  MMP-2 responsive mPEG-peptide diblock copolymer (PPDC) NPs   CPT and Sorafenib                                               *i.v.* injection every                                        Antiangiogenesis therapy and chemotherapy                        HT-29 tumor bearing mice                                                            [@B63]                       
  pH-sensitive poly(beta-amino ester) copolymer NPs            DOX and Cur                                                     *i.v.* injection                                              Antiangiogenesis therapy and chemotherapy                        SMMC 7721 tumor bearing mice                                                        [@B64]                       
  Captopril-polyethyleneimine conjugated AuNPs                 Captopril and siRNA                                             *i.v.* injection                                              Antiangiogenesis and gene therapy                                MDA-MB-435 tumor bearing mice                                                       [@B66]                       
  Calcium phosphate NPs                                        anti-VEGF shRNA and yCDglyTK                                    Intraperitoneal or intratumoral administration                Antiangiogenic gene therapy and suicide gene therapy             SGC7901 tumor bearing mice                                                          [@B67]                       
  CTX-coupled SNALP-formulated anti-miR-21 oligonucleotides    CTX and anti-miR-21                                             *i.v.* or oral administration                                 Antiangiogenesis therapy and gene therapy                        GBM tumor bearing mice                                                              [@B68]                       
  RhoJ antibody modified Au\@I NPs                             RhoJ antibody                                                   *i.v.* injection                                              Antiangiogenesis therapy and radiotherapy                        Patient-derived tumor xenografts                                                    [@B61]                       
  AuNPs                                                        anti-VEGF siRNA                                                 Intratumoral injection and laser irritation (655 nm)          Antiangiogenic gene therapy and photothermal therapy             PC-3 tumor bearing mice                                                             [@B31]                       
  Near infrared probe iron oxide NPs                           Bevacizumab                                                     *i.v.* injection                                              Antiangiogenesis therapy and imaging                             4T1 tumor bearing mice                                                              [@B58]                       
  Sorafenib and Ce6 formed carrier-free NPs                    Sorafenib and Ce6                                               *i.v.* injection and laser irritation (660 nm)                Antiangiogenesis therapy and photodynamic therapy                HSC3 tumor bearing mice                                                             [@B72]                       
  VDAs-based cancer starvation therapy                                                                                                                                                                                                                                                                                                                                         
  DOX-PLGA-conjugate NPs                                       Free CA4 and DOX                                                *i.v.* injection                                              Starvation therapy and chemotherapy                              Lewis lung carcinoma xenografts and B16F10 tumor bearing mice                       [@B23]                       
  LyP-1 coated liposomes                                       Free Ombrabulin and DOX                                         *i.v.* injection                                              Starvation therapy and chemotherapy                              MDA-MB-435 tumor bearing mice                                                       [@B74]                       
  Poly(L-glutamic acid)-*g*-mPEG NPs                           Free CA4P and CDDP                                              *i.v.* injection                                              Starvation therapy and chemotherapy                              MDA-MB-435 tumor bearing mice                                                       [@B75]                       
  A15-PGA-CDDP NPs                                             Free DMXAA and CDDP                                             *i.v.* injection                                              Starvation therapy and chemotherapy                              C26 tumor bearing mice                                                              [@B42]                       
  CA4-NPs                                                      CA4                                                             *i.v.* injection                                              Starvation therapy                                               C26 tumor bearing mice                                                              [@B28]                       
  mPEG-*b*-PHEA-DMXAA conjugate NPs                            DMXAA and DOX                                                   *i.v.* injection                                              Starvation therapy and chemotherapy                              MCF-7 tumor bearing mice                                                            [@B76]                       
  CA4-NPs                                                      CA4 and TPZ                                                     *i.v.* injection                                              Starvation therapy and chemotherapy                              4T1 tumor bearing mice                                                              [@B27]                       
  CA4-NPs and MMP9-DOX-NPs                                     CA4 and DOX                                                     *i.v.* injection                                              Starvation therapy and chemotherapy                              4T1 and C26 tumor bearing mice                                                      [@B78]                       
  Vascular blockade-induced cancer starvation therapy          CREKA modified IONPs and CRKDKC modified iron oxide nanoworms   Two tumor-homing peptide of CREKA and CRKDKC                  *i.v.* injection                                                 Starvation therapy                                                                  22Rv1 tumor bearing mice     [@B88]
  DNA nanorobots                                               Thrombin                                                        *i.v.* injection                                              Starvation therapy                                               MDA-MB-231 tumor bearing mice                                                       [@B26]                       
  PVP-modified Mg~2~Si NPs                                     Mg~2~Si                                                         Intratumoral injection                                        Starvation therapy                                               4T1 tumor bearing mice                                                              [@B11]                       
  TPZ-MNPs                                                     Mg~2~Si and TPZ                                                 Intratumoral injection                                        Starvation therapy and hypoxia-activated chemotherapy            4T1 tumor bearing mice                                                              [@B38]                       
  GOx-mediated cancer starvation therapy                       GOx-MnO~2~\@HA NPs                                              GOx and MnO~2~                                                Intratumoral injection                                           Starvation therapy                                                                  CT-26 tumor bearing mice     [@B98]
  Large pore-sized dendritic silica NPs                        GOx and Fe~3~O~4~ NPs                                           Intratumoral or *i.v.* injection                              Starvation therapy and oxidation therapy                         4T1 and U87 tumor xenografts                                                        [@B106]                      
  PEG-*b*-P(PBEM-*co*-PEM) NPs                                 GOx and QM                                                      *i.v.* injection                                              Starvation therapy and oxidation therapy                         A549 tumor bearing mice                                                             [@B101]                      
  Poly(FBMA-*co*-OEGMA) nanogels                               GOx                                                             Intratumoral injection                                        Starvation therapy and oxidation therapy                         C8161 tumor bearing mice                                                            [@B96]                       
  Fe~5~C~2~-GOx\@MnO~2~ NCs                                    GOx, Fe~5~C~2~ and MnO~2~                                       *i.v.* injection                                              Starvation therapy and oxidation therapy                         U14 and 4T1 tumor bearing mice                                                      [@B107]                      
  GOx-CPO\@ZIF-8\@NM NPs                                       GOx and CPO                                                     *i.v.* injection                                              Starvation therapy and oxidation therapy                         4T1 tumor bearing mice                                                              [@B109]                      
  ATP-responsive GOx\@ZIF\@MPN NPs                             GOx and Fe(III)/Fe(II)                                          Intratumoral injection e                                      Starvation therapy and oxidation therapy                         4T1 tumor bearing mice                                                              [@B108]                      
  FDMSNs\@GOx\@HA                                              GOx and Ferrocene                                               *i.v.* injection                                              Starvation therapy and oxidation therapy                         HeLa tumor bearing mouse                                                            [@B148]                      
  GOx\@PCPT-NR                                                 GOx and CPT prodrug                                             *i.v.* injection                                              Starvation therapy and chemotherapy                              A549 tumor bearing mice                                                             [@B41]                       
  Mem\@GOx\@ZIF-8\@BDOX) NPs                                   GOx and BDOX                                                    *i.v.* injection                                              Starvation therapy and chemotherapy                              4T1 tumor bearing mice                                                              [@B99]                       
  MSNs-GOx/PLL/HA                                              GOx and PTX                                                     *i.v.* injection                                              Starvation therapy and chemotherapy                              HepG2 tumor bearing mice                                                            [@B149]                      
  Yolk-shell tetrasulfide bond bridged dendritic MONs          GOx and AQ4N                                                    Intratumoral injection o                                      Starvation therapy and hypoxia-activated chemotherapy            4T1 tumor bearing mice                                                              [@B33]                       
  TGZ\@eM NRs                                                  GOx and TPZ                                                     *i.v.* injection                                              Starvation therapy and hypoxia-activated chemotherapy            CT26 tumor bearing mice                                                             [@B13]                       
  HA-coated CaCO~3~ NPs                                        GOx and TPZ                                                     *i.v.* injection                                              Starvation therapy and hypoxia-activated chemotherapy            CT26 tumor bearing mice                                                             [@B100]                      
  Liposomes                                                    GOx and AQ4N                                                    Intratumoral injection                                        Starvation therapy and hypoxia-activated chemotherapy            4T1 tumor bearing mice                                                              [@B30]                       
  BCE~TPZ~@(GOx+CAT)                                           GOx, CAT and TPZ                                                *i.v.* injection                                              Starvation therapy and hypoxia-activated chemotherapy            EMT-6 tumor bearing mice                                                            [@B94]                       
  GOx conjugated polymer dots                                  GOx                                                             Intratumoral injection and laser irritation (460 nm)          Starvation therapy and photodynamic therapy                      MCF-7 tumor bearing mice                                                            [@B115]                      
  Mem\@catalase\@GOx\@PCN-224 bioreactor                       GOx, CAT and TCPP                                               *i.v.* injection and laser irritation (660 nm)                Starvation therapy and photodynamic therapy                      4T1 tumor bearing mice                                                              [@B44]                       
  HMSNs                                                        GOx and Ce6                                                     *i.v.* injection                                              Starvation therapy and photodynamic therapy                      B16F10 metastatic tumor bearing mice                                                [@B32]                       
  Hollow-MnO~2~-GOx-Ce6\@CM                                    GOx, MnO~2~ and Ce6                                             *i.v.* injection and laser irritation (655 nm)                Starvation therapy and photodynamic therapy                      B16F10 tumor bearing mice                                                           [@B150]                      
  rMGB                                                         GOx, MnO~2~ and Ce6                                             *i.v.* injection and laser irridation (660 nm)                Starvation therapy and photodynamic therapy                      4T1 cancer bearing mice                                                             [@B120]                      
  PEGylate HA-functionalized PHPBNs                            GOx                                                             *i.v.* injection and NIR laser irritation (808 nm)            Starvation therapy and photothermal therapy                      HepG2 tumor bearing mice                                                            [@B121]                      
  BSA-directed two-dimensional MnO~2~ nanosheet                MnO~2~                                                          *i.v.* injection and NIR laser irritation (808 nm)            Starvation therapy and photothermal therapy                      U87MG tumor bearing mice                                                            [@B122]                      
  GOx-conjugated silver nanocubes                              GOx and Ag ions                                                 Intratumoral injection                                        Starvation therapy and metal ion therapy                         4T1 tumor bearing mice                                                              [@B113]                      
  HMONs                                                        L-Arg and GOx                                                   Intratumoral injection                                        Starvation therapy and gas therapy                               U87MG tumor bearing mice                                                            [@B46]                       
  CMSNs                                                        GOx and anti-PD-1                                               *i.v.* injection                                              Starvation therapy and immunotherapy                             B16F10 tumor bearing mice                                                           [@B47]                       
  Fe~3~O~4~\@PPy\@GOx NCs.                                     GOx, Fe~3~O~4~ NPs and PPy                                      *i.v.* injection and NIR laser irradiation (808 or 1064 nm)   Starvation therapy, oxidation therapy and photodynamic therapy   4T1 tumor bearing mice                                                              [@B45]                       
                                                               CPT\@MOF(Fe)-GOx                                                GOx, Fe^3+^ and CPT                                           Intratumoral injection                                           Starvation therapy, oxidation therapy and chemotherapy                              HeLa tumor bearing mice      [@B151]
                                                               MGH nanoamplifier                                               GOx and MIL-100                                               *i.v.* injection, NIR laser irradiation (808 nm)                 Starvation therapy, oxidation therapy, photothermal therapy and imaging             4T1 tumor bearing mice       [@B110]
  Other strategies for cancer starvation therapy               HDL-AuNPs                                                       HDL                                                           *i.v.* injection                                                 Starvation therapy                                                                  B-cell lymphoma xenografts   [@B39]
  HDL-AuNPs                                                    HDL                                                             *i.v.* injection                                              Starvation therapy and immunotherapy                             LLC tumor bearing mice and melanoma metastatic lung colonization mice model         [@B140]                      
  CHC-PZM\@HA                                                  CHC and PZM                                                     *i.v.* injection, laser irradiation (660 nm)                  Starvation therapy and photodynamic therapy                      CT26 tumor bearing mice                                                             [@B40]                       
  Mn-D\@BPFe-A NPs                                             DOX, Fe^3+^                                                                                                                   Starvation therapy, chemotherapy and photodynamic therapy        HepG2 tumor bearing mice                                                            [@B141]                      
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List of abbreviations

  ------------------------- -----------------------------------------------------------------------------------------------
  ∙OH                       Hydroxyl radical
  ^1^O~2~                   Singlet oxygen
  2D                        Two-dimensional
  4T1                       Mice breast tumor cell line
  22Rv1                     Human prostate cancer cell line
  A431                      Human epidermoid carcinoma cell line
  A549                      Human lung cancer cell line
  Ag                        Silver
  AIA                       Angiogenesis inhibiting agent
  anti-PD-1                 Programmed cell death protein 1 antibody
  anti-PD-L1                Programmed cell death ligand 1 antibody
  AQ4N                      Banoxantrone dihydrochloride
  AXT                       Axitinib
  ATP                       Adenosine triphosphate
  Au NP                     Gold nanoparticle
  B16F10                    Mouse melanoma cell line
  BDOX                      H~2~O~2~-sensitive doxorubicin prodrug
  BPEI                      Branched polyethylenimine
  BSA                       Bovine serum albumin
  BCE                       PEG-*b*-PHEMA crosslinked CPZ loaded BSA and CAT/GOx nanoclustered enzymes
  C26                       Murine colon cancer cell line
  C8161                     Human melanoma cell line
  CT26                      Mouse colon cancer cell line
  CA4                       Combretastatin A4
  CA4P                      Combretastatin A4 disodium phosphate
  CA4-NPs                   Poly(L-glutamic acid)-CA4 conjugate nanoparticles
  CDDP                      Cisplatin
  Ce6                       Chlorin e6
  CHC                       *α*-cyano-4-hydroxycinnamate
  CM                        Cell membrane
  CMSNs                     Cancer cell membrane coated mesoporous silica nanoparticles
  CPNP                      Calcium phosphate nanoparticle
  CPO                       Chloroperoxidase
  CPPO                      Bis\[2,4,5-trichloro-6-(pentyloxycarbonyl)phenyl\]oxalate
  CPT                       Camptothecin
  CST                       Celastrol
  CTX                       Chlorotoxin
  Cur                       Curcumin
  DDS                       Drug delivery system
  DCs                       Dendritic cells
  DMXAA                     5,6-dimethylxanthenone-4-acetic acid
  DOX                       Doxorubicin
  ECs                       Endothelial cells
  EEPT                      Enzyme-enhanced phototherapy
  eM                        Erythrocyte membrane
  EMT-6                     Mouse mammary cancer cell line
  EPR                       Enhanced permeability and retention
  FDA                       Food and Drug Administration
  FDMSNs                    Ferrocene-functionalized dendritic mesoporous silica nanoparticles
  GBM                       Human glioblastoma cell line
  GO                        Graphene oxide
  GOx                       Glucose oxidase
  GSH                       Glutathione
  H~2~O~2~                  Hydrogen peroxide
  HA                        Hyaluronic acid
  HAP                       Hypoxia-activated prodrug
  HDL                       High density lipoprotein
  HFR                       Heparin-folic acid-retinoic acid conjugate
  HMON                      Hollow mesoporous organosilica nanoparticle
  H22                       Mouse hepatocellular carcinoma cell line
  HepG2                     Human liver cancer cell line
  HSC3                      Human oral squamous carcinoma cell line
  HSP                       Heat shock protein
  HT-29                     Mouse colon tumor cell line
  ICG                       Indocyanine green
  ICB                       Immune checkpoint blockade
  iNGR-NP                   iNGR-modified PEG-PLGA nanoparticle
  iNOS                      NO synthase enzyme
  IONP                      Iron oxide nanoparticle
  *i.v.*                    Intravenous injection
  LyP-1                     Phage-displayed cyclic peptide
  LLC                       Lewis lung carcinoma cell line
  MCF-7                     Human breast cancer cell line
  MCT1                      Monocarboxylate transporter 1
  MDA-MB-435                Human breast cancer cell line
  MDA-MB-231                Human breast cancer cell line
  MDR                       Multidrug resistance
  MDSCs                     Myeloid-derived suppressor cells
  Mg~2~Si                   Magnesium silicide
  MGP                       GOx and MnCO coloaded poly(lactic-co-glycolic acid) nanoparticles
  MIL-100                   Ferric ions contained metal organic framework
  MGH                       GOx loaded MIL-100 with polydopaminemodified hyaluronic acid coating
  MMC                       Mitomycin C
  MMP                       Matrix metalloproteinase
  MnO~2~                    Manganese dioxide
  M-NS                      BSA-directed two-dimensional MnO~2~ nanosheet
  MOF                       Metal-organic framework
  MOST                      Multispectral optoacoustic tomography
  MPN                       Metal polyphenol network
  MSN                       Mesoporous silica nanoparticle
  MTX                       Methotrexate
  nano-DOA                  Nano-deoxygenation agent
  NC                        Nanocatalyst
  NIR                       Near-infrared
  NM                        Neutrophil membrane
  NO                        Nitric oxide
  NP                        Nanoparticle
  NR                        Nanoreactor
  O~2~                      Oxygen
  OCl^-^                    Hypochlorite ion
  OSCC                      Oral squamous carcinoma cell line
  PC-3                      Human prostate cancer cell line
  Pdot                      Polymer dot
  PDT                       Photodynamic therapy
  PFC                       Perfluorocarbon
  PLA                       Poly-L-arginine
  PLL                       poly (L-lysine)
  PLGA                      Polylactic-*co*-glycolic acid
  PEG                       Poly(ethylene glycol)
  PEG-*b*-PHEMA             poly(ethylene glycol)-*block*-poly(2-hydroxyethyl methacrylate)
  PLG-*g*-mPEG              Poly(L-glutamic acid)-*g*-methoxy poly(ethylene glycol)
  PPy                       Polypyrrole
  PTT                       Photothermal therapy
  PTX                       Paclitaxel
  PVP                       Polyvinyl pyrrolidone
  PZM                       Porous Zr (IV)-based porphyrinic metal-organic framework
  RA                        Retinoic acid
  RBC                       Red blood cell
  RGD                       Arginine-glycine-aspartic acid
  rMGB                      Biomimetic hybrid nanozyme with a GOx/MnO~2~/BSA-Ce6 core and red blood cell membrane coating
  ROS                       Reactive oxygen species
  SCC7                      Murine squamous cell carcinoma cell line
  SGC7901                   Gastric cancer cell line
  shVEGF                    VEGF-targeted small hairpin RNA
  SiO~2~                    Silicon dioxide
  siRNA                     Small interfering RNA
  SMMC 7721                 Human liver tumor cell line
  SR-B1                     Scavenger receptor type B-1
  SW620                     Human Caucasian colon adenocarcinoma cell line
  TACE                      Transarterial chemoembolization
  TAF                       Tumor angiogenesis factor
  TCPP                      Tetrakis (4-carboxyphenyl) porphyrin
  THP                       Tumor-homing peptide
  TME                       Tumor microenvironment
  TPZ                       Tirapazamine
  UV                        Ultraviolet
  VDA                       Vascular disrupting agent
  VEGF                      Vascular endothelial growth factor
  U14                       Mouse cervical subcutaneous cancer cell line
  U87                       Human glioblastoma cell line
  U87MG                     Human glioblastoma cell line
  Vx2                       Rabbit carcinoma cell line
  yCDglyTK                  Fusion suicide gene
  ZIF-8                     Zeolitic imidazolate framework-8
  *α*~v~*β*~3~-Dxtl-PD NP   *α*~v~*β*~3~-integrin targeted perfluorocarbon nanoparticle
  ------------------------- -----------------------------------------------------------------------------------------------

[^1]: Competing Interests: The authors have declared that no competing interest exists.
